MedTrace Logo

A Naturalistic Prospective Study of Treatment Effectiveness for Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00323700 · Status: WITHDRAWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2009-04-21

No results posted yet for this study

Summary

To determine if there is a clinically and statistically significant difference between OROS-MPH and IR MPH in ADHA and ODD symptoms by the parent completed SNAP-IV. It is hypothesized that OROS-MPH is superior in improving symptom outcomes overall, remission rate, functional improvement, quality of life and persistence with medication over time.

Conditions

  • Attention-Deficit/Hyperactivity Disorder (ADHD)

Sponsors & Collaborators

  • Janssen-Ortho Inc., Canada

    collaborator INDUSTRY

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Margaret Weiss, MD · The University of British Columbia

Eligibility

Min Age
16 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2010-12-31
Completion
2010-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00323700 on ClinicalTrials.gov